Makers of a new respiratory syncytial virus (RSV) vaccine for infants confirmed that they will make available an additional 230,000 doses for infants in January, the White House said today, following meeting yesterday with representatives from Sanofi, AstraZeneca, and their partners.

The announcement is on top of 77,000 additional doses of Beyfortus that were released in November. Beyfortus (nirsevimab-alip) is a new long-acting monoclonal antibody injection to protect newborns against RSV. Unprecedented demand—well above what the companies expected—for the injection has led to some supply problems.
The White House said it has had several virtual and in-person meetings with drug makers to ensure they are identifying every opportunity to boost the supply of Beyfortus. Senior officials and company representatives are also continuing conversations on the importance of proactively planning to meet demand for the 2024-2025 season.
Beyfortus is one of two new tools available this season for preventing RSV in the youngest children, who are among the highest risk for infection complications. In August, the FDA approved the use of Pfizer’s new RSV vaccine, called Abrysvo, in pregnant women as a strategy for protecting newborns. In early September, the Center for Disease Control and Prevention's vaccine advisory group recommended that pregnant women between 32 to 36 weeks' gestation receive the vaccine as a single intramuscular dose.